Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

NCT00727064 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Desvenlafaxine Succinate Sustained-Release (DVS SR)
DRUG: Venlafaxine Extended Release (VEN ER)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer